Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
PS-341 in Treating Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00028639
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- University of Wisconsin, Madison
- Registration Number
- NCT00023855
- Locations
- 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00028912
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Bortezomib in Treating Patients With Mantle Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 30
- Registration Number
- NCT00030875
- Locations
- 🇨🇦
Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00023881
- Locations
- 🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
PS-341 in Treating Patients With Metastatic Kidney Cancer
- Conditions
- Kidney Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00017329
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Bortezomib in Treating Patients With Lymphoproliferative Disorders
- Conditions
- Recurrent Mantle Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 1 Follicular Lymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 103
- Registration Number
- NCT00023764
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: bortezomibDrug: carboplatinDrug: etoposideOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT00027898
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
Bortezomib in Treating Children With Advanced Solid Tumors
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00021216
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Bortezomib in Treating Patients With Recurrent Glioma
- Conditions
- Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00006773
- Locations
- 🇺🇸
New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.